TACSTD2 and cholangiocarcinoma: Given that there is no molecular‐targeted therapy in the standard of care for PC and CC patients and that TROP2 is overexpressed in about half of PC and CC specimens, TROP2‐targeted PIT is an attractive candidate for clinical trials and ultimately treatment.